Naesens M, Loupy A, Hilbrands L, Oberbauer R, et al. Rationale for Surrogate Endpoints and Conditional Marketing Authorization of New Therapies for Kidney Transplantation. Transpl Int 2022;35:10137.
PMID: 35669977